HealthEquity director sells 7,632 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
HEALTHEQUITY, INC. (HQY) director Adrian T. Dillon reported an option exercise and related stock sales. On August 25, 2026, he exercised a stock option for 7,632 shares of common stock at an exercise price of $32.50 per share, acquiring 7,632 shares of common stock.
On the same date, he sold 6,300 shares of common stock at a weighted average price of $104.4718 per share and 1,332 shares at a weighted average price of $105.2557 per share. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on December 20, 2025. Dillon continues to hold several stock options with exercise prices between $46.40 and $66.06 expiring from 2027 to 2030.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,632 shares ($550K approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
DILLON ADRIAN T
Role
Director
Sold
7,632 shs ($798K)
Approx. gross sale proceeds
$798K
Approx. exercise cost
$248K
Approx. pre-tax spread
$550K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F4 | 7,632 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 7,632 | $32.50 | $248K |
| Sale | Common Stock F1, F2 | 6,300 | $104.4718 | $658K |
| Sale | Common Stock F1, F3 | 1,332 | $105.2557 | $140K |
| holding | Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Stock Option (right to buy) F4 | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 16,814 contracts (Direct);
Common Stock — 62,395 shares (Direct)
Footnotes (4)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.10 to $105.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 of this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.10 to $105.53, inclusive.
- F4. The option is immediately exercisable.
Key Figures
Option shares exercised: 7,632 shares
Option exercise price: $32.50 per share
Shares sold (first tranche): 6,300 shares
+5 more
8 metrics
Option shares exercised
7,632 shares
Stock option exercise into common stock on August 25, 2026
Option exercise price
$32.50 per share
Exercise price for 7,632-share stock option
Shares sold (first tranche)
6,300 shares
Common stock sale at weighted average price of $104.4718 on August 25, 2026
Weighted average sale price (first tranche)
$104.4718 per share
Sale of 6,300 shares in multiple transactions
Shares sold (second tranche)
1,332 shares
Common stock sale at weighted average price of $105.2557 on August 25, 2026
Weighted average sale price (second tranche)
$105.2557 per share
Sale of 1,332 shares in multiple transactions
Remaining option exercise price range
$46.40–$66.06 per share
Exercise prices of remaining stock options expiring 2027–2030
Remaining option underlying shares
16,814 shares
Sum of underlying shares across four remaining option grants
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), underlying security
4 terms
Rule 10b5-1 trading plan regulatory
"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
underlying security financial
"underlying_security_title: Common Stock"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did HQY director Adrian T. Dillon report on August 25, 2026?
Adrian T. Dillon exercised a stock option for 7,632 shares of HealthEquity, Inc. common stock at an exercise price of $32.50 per share and sold 7,632 shares in total in two transactions on August 25, 2026.
Was Adrian T. Dillon’s HQY trading done under a Rule 10b5-1 plan?
Yes. A footnote states the transactions reported were effected pursuant to a Rule 10b5-1 trading plan adopted by Adrian T. Dillon on December 20, 2025.
What HQY stock options does Adrian T. Dillon continue to hold after this Form 4?
He continues to hold stock options over 4,837 underlying shares at $46.40, 4,339 at $50.41, 3,626 at $63.64, and 4,012 at $66.06, with expiration dates from February 1, 2027 through February 1, 2030.
AI-generated analysis. How Rhea-AI works. Not financial advice.
